InsiderTrades.com logo
This is treason
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

MNPR Insider Trading

Insider Ownership Percentage: 34.90%
Insider Buying (Last 12 Months): $61,373.70
Insider Selling (Last 12 Months): $0.00

Monopar Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Monopar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Monopar Therapeutics Share Price & Price History

Current Price: $15.50
Price Change: ▼ Price Decrease of -0.71 (-4.38%)
As of 10/30/2024 12:45 PM ET

This chart shows the closing price history over time for MNPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
This is treason
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

Monopar Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2024Andrew CittadineCOOBuy4,101$3.70$15,173.7037,226View SEC Filing Icon  
6/17/2024Andrew CittadineCOOBuy2,400$4.50$10,800.0030,724View SEC Filing Icon  
6/13/2024Andrew CittadineCOOBuy2,400$4.55$10,920.0025,924View SEC Filing Icon  
6/3/2024Andrew CittadineCOOBuy2,400$3.80$9,120.0021,124View SEC Filing Icon  
5/31/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0018,724View SEC Filing Icon  
5/29/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0013,924View SEC Filing Icon  
11/14/2022Andrew CittadineCOOBuy1,210$15.00$18,150.002,847View SEC Filing Icon  
See Full Table
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Monopar Therapeutics (NASDAQ:MNPR)

1.83% of Monopar Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Monopar Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC28,761$0.17M0.0%+9.0%0.229%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.97,462$0.57M0.0%+116.2%0.775%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp36,001$0.22M0.0%-38.8%0.286%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC26,394$0.16M0.0%N/A0.210%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.11,229$70K0.0%+108.3%0.089%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp58,793$0.36M0.0%-9.2%0.513%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.5,391$33K0.0%+99.4%0.047%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Monopar Therapeutics logo
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More on Monopar Therapeutics

Today's Range

Now: $15.50
Low: $14.77
High: $16.03

50 Day Range

MA: $5.46
Low: $2.26
High: $32.66

52 Week Range

Now: $15.50
Low: $1.37
High: $38.50

Volume

137,242 shs

Average Volume

711,620 shs

Market Capitalization

$54.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Monopar Therapeutics?

Monopar Therapeutics' top insider investors include:
  1. Andrew Cittadine (COO)
Learn More about top insider investors at Monopar Therapeutics.
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes   |   Ad
Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.
Click here to see the surprising reason why